Foundation Medicine Inc. announced a nationwide contract with the U.S. Department of Veterans Affairs National Precision Oncology Program to provide comprehensive genomic profiling for eligible Veterans with advanced cancer.
The contract covers all of Foundation Medicine’s available tests, including FoundationOne CDx and FoundationOne Liquid for solid tumors, as well as FoundationOne Heme for hematologic malignancies.
“Foundation Medicine is honored to be awarded a contract to provide comprehensive genomic profiling for veterans with advanced cancer,” Cindy Perettie, chief executive officer at Foundation Medicine, said in a statement. “This decision by the VA as well as Medicare’s National Coverage Determination issued in early 2018 mark important steps forward in access to personalized cancer care.”
